ArticleThe Journal of urology2019

Re: Axitinib versus Placebo as an Adjuvant Treatment of Renal Cell Carcinoma: Results from the Phase III, Randomized ATLAS Trial.

M Pilar LagunaPubMed ↗Publisher ↗

No numbers read from the abstract.